Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)
- PMID: 37743037
- DOI: 10.1016/j.cgh.2023.09.010
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)
Abstract
Background & aims: Although biologics have revolutionized the treatment of Crohn's disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates.
Methods: EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, and then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2, then 40 mg every 2 weeks), and methotrexate (15 mg weekly) in biologic-naïve patients with newly diagnosed, moderate- to high-risk CD. Endoscopic remission at week 26 (primary end point; Simple Endoscopic Score for CD ≤2), clinical remission at weeks 10 and 26 (secondary end point; Crohn's Disease Activity Index <150), and incidences of adverse events and serious adverse events were evaluated.
Results: Among 55 enrolled patients, the mean CD duration was 0.4 years, the mean baseline Simple Endoscopic Score for CD was 12.6, and the mean baseline Crohn's Disease Activity Index was 265.5. At week 26, 19 patients (34.5%) were in endoscopic remission. At weeks 10 and 26, 34 (61.8%) and 30 patients (54.5%), respectively, were in clinical remission. Post hoc Bayesian analysis showed that the probabilities that triple combination therapy produced a higher endoscopic remission rate (33.5%; 95% credible interval, 22.4-45.7) than placebo (14%), vedolizumab monotherapy (27%), or adalimumab monotherapy (30%) were 99.9% or higher, 86.3%, and 71.4%, respectively. Six patients had serious adverse events.
Conclusions: Combination therapy resulted in endoscopic and clinical remission at week 26 in 34.5% and 54.5% of patients, respectively, with no safety signal related to the treatment regimen. This supports further evaluation of combination therapy in CD.
Clinicaltrials: gov number: NCT02764762.
Keywords: Biologic; Combination Therapy; Crohn’s Disease; EXPLORER; Vedolizumab.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34688373 Free PMC article.
-
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719. Epub 2020 Apr 24. Aliment Pharmacol Ther. 2020. PMID: 32329532 Free PMC article.
-
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.Gastroenterology. 2019 Oct;157(4):1007-1018.e7. doi: 10.1053/j.gastro.2019.06.038. Epub 2019 Jul 4. Gastroenterology. 2019. PMID: 31279871 Clinical Trial.
-
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.Cochrane Database Syst Rev. 2018 May 12;5(5):CD012540. doi: 10.1002/14651858.CD012540.pub2. Cochrane Database Syst Rev. 2018. PMID: 29756637 Free PMC article. Review.
-
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.Cochrane Database Syst Rev. 2014 Aug 1;2014(8):CD010233. doi: 10.1002/14651858.CD010233.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2019 Aug 06;8:CD010233. doi: 10.1002/14651858.CD010233.pub3. PMID: 25081347 Free PMC article. Updated. Review.
Cited by
-
Optimal Management of Refractory Crohn's Disease: Current Landscape and Future Direction.Clin Exp Gastroenterol. 2024 Mar 26;17:75-86. doi: 10.2147/CEG.S359376. eCollection 2024. Clin Exp Gastroenterol. 2024. PMID: 38558912 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical